Market Overview:
DTaP vaccine is a combination vaccine that protects against diphtheria, tetanus, and pertussis. The global DTaP vaccine market is expected to grow at a CAGR of 7.5% during the forecast period 2018-2030. North America dominates the global DTaP vaccine market followed by Europe and Asia Pacific region. Increasing incidence of diphtheria, tetanus, and pertussis in adults & pediatric population are some of the major factors driving the growth of global DTaP vaccine market. Moreover, increasing awareness about benefits associated with vaccination is also fuelling the growth of this market.
 Vaccine Industry Outlook.svg)
Product Definition:
The DTaP vaccine is a combination vaccine that protects against diphtheria, tetanus, and pertussis. Diphtheria is a serious illness caused by a bacterial infection. Tetanus is also a serious illness caused by bacteria and can lead to death. Pertussis (whooping cough) is a highly contagious respiratory illness that can cause severe coughing spells and difficulty breathing. The DTaP vaccine helps protect children from these illnesses.
Immune DTaP Vaccine:
Immune D TaP vaccine is a live attenuated vaccine, which is used for the prevention of diseases such as diphtheria, tetanus and pertussis. The product was approved by the U.S Food and Drug Administration (FDA) in 1995 under 21 CFR part 862 - Immunityproducing Vaccines.
Therapy DTaP Vaccine:
The Centers for Disease Control and Prevention (CDC) recommends that adults aged 65 years and above are fully vaccinated against diphtheria, tetanus, and pertussis. The American Academy of Orthopedic Surgeons also recommends the vaccination for adults aged 70 years and above. However, there is no evidence to support either claim as fact.
Application Insights:
On the basis of application, the global DTaP vaccine market is categorized into adult and pediatric populations. The adult segment held a larger share in 2017 as compared to pediatric population due to higher number of immunization against diphtheria, tetanus and pertussis in adults.
The growing importance of immunization against diphtheria, tetanus and pertussis among adults as a result of availability of effective vaccines for these diseases coupled with rising incidences among adults is expected to drive demand over the forecast period. Adult vaccination requires only one dose per person whereas multiple doses are required for protection from whooping cough disease in children.
DTaP vaccines are highly effective against whooping cough; however, less efficient than whole cell Pertussis (WCP) vaccines regarding prevention from transmission via respiratory droplets.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to high immunization coverage, favorable reimbursement policies, and increasing awareness about vaccines. The U.S., which is the most developed country regarding healthcare infrastructure and technology has one of the highest immunization rates in the world with over 92% coverage for diphtheria, pertussis, and tetanus (DPT) vaccine according to data published by WHO/IMSD in 2016.
Growth Factors:
- Increasing incidence of diphtheria, tetanus, and pertussis (DTaP) infections across the globe
- Growing awareness about the benefits of DTaP vaccine among parents and healthcare professionals
- Rising demand for safe and effective vaccines to prevent diphtheria, tetanus, and pertussis (DTaP) infections
- Technological advancements in vaccine development process
- increasing government initiatives to promote vaccination against diphtheria, tetanus, and pertussis (DTaP)
Scope Of The Report
Report Attributes
Report Details
Report Title
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Research Report
By Type
Immune DTaP Vaccine, Therapy DTaP Vaccine
By Application
Adult, Pediatric
By Companies
Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Inc, Pfizer Inc, Johnson & Johnson, Lanzhou Institute of Biological Products Co., Ltd, AstraZeneca, Emergent BioSolutions Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Report Segments:
The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is segmented on the basis of:
Types
Immune DTaP Vaccine, Therapy DTaP Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adult, Pediatric
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi Pasteur
- GlaxoSmithKline
- Protein Sciences Corporation
- Novartis AG
- Seqirus
- Merck Sharp & Dohme Corp
- Astellas Pharma US, Inc
- Pfizer Inc
- Johnson & Johnson
- Lanzhou Institute of Biological Products Co., Ltd
- AstraZeneca
- Emergent BioSolutions Inc
 Vaccine Market Overview.svg)
Highlights of The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immune DTaP Vaccine
- Therapy DTaP Vaccine
- By Application:
- Adult
- Pediatric
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Vaccine Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
DTaP vaccine is a combination vaccine that protects against diphtheria, tetanus, and pertussis (whooping cough). It is recommended for children aged 2 months through 6 years.
Some of the major companies in the diphtheria, tetanus, and pertussis (dtap) vaccine market are Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Inc, Pfizer Inc, Johnson & Johnson, Lanzhou Institute of Biological Products Co., Ltd, AstraZeneca, Emergent BioSolutions Inc.
The diphtheria, tetanus, and pertussis (dtap) vaccine market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market - Supply Chain
4.5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast
4.5.1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Absolute $ Opportunity
5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Type
5.3.1. Immune DTaP Vaccine
5.3.2. Therapy DTaP Vaccine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Application
6.3.1. Adult
6.3.2. Pediatric
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Demand Share Forecast, 2019-2029
9. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Application
9.4.1. Adult
9.4.2. Pediatric
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Type
9.7.1. Immune DTaP Vaccine
9.7.2. Therapy DTaP Vaccine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Demand Share Forecast, 2019-2029
10. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Application
10.4.1. Adult
10.4.2. Pediatric
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Type
10.7.1. Immune DTaP Vaccine
10.7.2. Therapy DTaP Vaccine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Demand Share Forecast, 2019-2029
11. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Application
11.4.1. Adult
11.4.2. Pediatric
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Type
11.7.1. Immune DTaP Vaccine
11.7.2. Therapy DTaP Vaccine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Demand Share, 2019-2029
12. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Application
12.4.1. Adult
12.4.2. Pediatric
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Type
12.7.1. Immune DTaP Vaccine
12.7.2. Therapy DTaP Vaccine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Demand Share, 2019-2029
13. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Application
13.4.1. Adult
13.4.2. Pediatric
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and Volume Forecast by Type
13.7.1. Immune DTaP Vaccine
13.7.2. Therapy DTaP Vaccine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market: Market Share Analysis
14.2. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors and Customers
14.3. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi Pasteur
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GlaxoSmithKline
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Protein Sciences Corporation
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Seqirus
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck Sharp & Dohme Corp
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Astellas Pharma US, Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Pfizer Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Johnson & Johnson
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Lanzhou Institute of Biological Products Co., Ltd
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. AstraZeneca
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Emergent BioSolutions Inc
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
